- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Piramal Pharma has infused a significant ₹ 1,626.49 Cr into PPL Pharma Inc., its wholly-owned step-down subsidiary. This substantial capital infusion, through preference share subscription by Piramal Healthcare Inc., aims to fortify the subsidiary's financial standing. The move is a strategic internal deployment of capital to strengthen existing group assets, supporting PPL Pharma Inc.'s ongoing operations and future growth initiatives. This isn't an external acquisition, but a balance sheet boost for an already owned entity.